Brii Biosciences Limited (BRII-B) has circulated a proxy form outlining the resolutions to be tabled at its online annual general meeting on 16 June 2026 at 8:00 a.m. (Hong Kong time).

Key resolutions are as follows:

1. Financial Statements • Shareholders will vote on the adoption of the audited consolidated financial statements for the year ended 31 December 2025, together with the directors’ and auditor’s reports.

2. Board Composition and Remuneration • Re-election of Dr. Zhi Hong as an executive director. • Re-election of Dr. Martin J Murphy Jr and Dr. Taiyin Yang as independent non-executive directors. • Authorisation for the board to fix directors’ remuneration.

3. Auditor Appointment • Proposal to re-appoint Deloitte Touche Tohmatsu as external auditor until the next AGM and to authorise the board to determine its fees.

4. Share Capital Mandates • General mandate allowing the board to issue, allot or transfer shares— including treasury shares—up to 20% of the company’s issued share capital as of the AGM date. • Authorisation to buy back up to 10% of issued shares (excluding treasury shares). • Conditional extension of the issuance mandate by the number of shares repurchased under the buy-back authority.

The meeting will be conducted exclusively via the Vistra eVoting Portal; shareholders intending to appoint a proxy other than the chairman must provide a valid email address to Tricor Investor Services by 14 June 2026 at 8:00 a.m. Hong Kong time.